Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Receivables (2018 - 2025)

TELA Bio has reported Receivables over the past 8 years, most recently at $10.3 million for Q4 2025.

  • Quarterly results put Receivables at $10.3 million for Q4 2025, up 2.47% from a year ago — trailing twelve months through Dec 2025 was $10.3 million (up 2.47% YoY), and the annual figure for FY2025 was $10.3 million, up 2.47%.
  • Receivables for Q4 2025 was $10.3 million at TELA Bio, down from $11.3 million in the prior quarter.
  • Over the last five years, Receivables for TELA hit a ceiling of $11.3 million in Q3 2025 and a floor of $2.8 million in Q1 2021.
  • Median Receivables over the past 5 years was $8.0 million (2023), compared with a mean of $7.6 million.
  • Biggest five-year swings in Receivables: soared 59.19% in 2022 and later increased 0.46% in 2025.
  • TELA Bio's Receivables stood at $4.2 million in 2021, then soared by 56.38% to $6.6 million in 2022, then surged by 47.06% to $9.7 million in 2023, then increased by 3.71% to $10.1 million in 2024, then increased by 2.47% to $10.3 million in 2025.
  • The last three reported values for Receivables were $10.3 million (Q4 2025), $11.3 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.